Market Place
Sourcing Support
Discover our 2023 Sustainability Report
07 Oct 2024 //
PRESS RELEASE
Ferrer Advances Research Into Progressive Supranuclear Palsy With Phase 2 Trial
17 Sep 2024 //
BUSINESSWIRE
Ferrer Advances Research Into PSP First Participant Ph II Trial
08 Aug 2024 //
PRESS RELEASE
Ferrer Acquires Worldwide Rights to ASN90
22 Feb 2023 //
BUSINESSWIRE
Ferrer Invests More Than 60% of Net Profits in Social and Environmental Causes
28 Jul 2022 //
BUSINESSWIRE
Ferrer, strategic partner of Barcelona+B, the initiative to promote a prosperous
26 Apr 2022 //
PRESS RELEASE
More than 400 employees from Ferrer take part in a social initiative in Spain
08 Apr 2022 //
PRESS RELEASE
Improving clinical research for people with Cyclic Vomiting Syndrome (CVS)
11 Mar 2022 //
PRESS RELEASE
Ferrer, the first pharmaceutical company committed to recovering waste medicines
09 Mar 2022 //
PRESS RELEASE
Ferrer brings the first PHantasticals to lifeawareness of Pulmonary Hypertension
05 Mar 2022 //
PRESS RELEASE
Details of Clinical Trial ADORE for Amyotrophic Lateral Sclerosis (ALS)
24 Feb 2022 //
PRESS RELEASE
Ferrer announces distribution agreement United Therapeutics for treprostinil
23 Feb 2022 //
PRESS RELEASE
Ferrer becomes a B Corp for its positive impact in society
25 Jan 2022 //
PRESS RELEASE
Ferrer joins Barcelona + B, project to bring the business community closer SDGs
29 Nov 2021 //
PRESS RELEASE
First patient enrolled in Ferrer`s FNP122 ADORE Phase III clinical trial
08 Nov 2021 //
PRESS RELEASE
Ferrer signs license agreement to develop an oral formulation treatment
20 Oct 2021 //
PRESS RELEASE
We launched the third edition of the Ferrer 4 Future program
07 Jun 2021 //
PRESS RELEASE
Ferrer is certified as an excellent place to work, putting people at the center of its cultural transformation
22 Apr 2021 //
PRESS RELEASE
Ferrer launches one of the most effective oral lipid-lowering agents on the market
25 Feb 2021 //
PRESS RELEASE
Ferrer takes a further step in its strategy and diverts from HealthTech BioActives
13 Dec 2020 //
PRESS RELEASE
We are strongly committed to sustainability and we are adopting measures to promote the circular economy
18 Jun 2020 //
PRESS RELEASE
Ferrer launches a new, disruptive, more accessible corporate website focused on transparency
18 Jun 2020 //
PRESS RELEASE
Ferrer cooperates with the Hospital del Mar de Barcelona in a project on COVID-19
18 Jun 2020 //
PRESS RELEASE
Add Interquim Project: PCS7 updating project in a regulated Pharma environment
02 Mar 2020 //
PRESS RELEASE
Riverside Acquires Pharma and Food Ingredients Biz from Ferrer
18 Dec 2019 //
PR NEWSWIRE
Ferrer unloads another business to focus on branded drugs
17 Dec 2019 //
FIERCE PHARMA
Ferrer workers exchange office tools for picks and shovels
28 Aug 2019 //
PRESS RELEASE
FDA has no objections to GRAS status of Spanish firm’s hesperidin
11 Mar 2019 //
NUTRAINGREDIENT
Ricardo Castrillo, new CEO of Ferrer Spain
01 Oct 2018 //
PRESS RELEASE
A project on education in physical pain, SEDAP-Ferrer award from Castilla y León
18 May 2018 //
PRESS RELEASE
Medimetriks Pharmaceuticals Divests Xepi™ Cream to Cutanea Life Sciences, Inc.
05 Mar 2018 //
PR NEWSWIRE
Newly Approved Impetigo Med to be Commercialized by Cutanea Life Sciences, Inc.
05 Mar 2018 //
PR NEWSWIRE
Mario Rovirosa named new Ferrer CEO
03 Feb 2018 //
PRESS RELEASE
AMRI, Ferrer & Accord enter pact to develop parenteral drug products
23 Feb 2017 //
PHARMABIZ
Ferrer opens its new facilities in Beniel
22 Sep 2016 //
ELGLOBAL
Alexza Pharmaceuticals Acquired by Ferrer
22 Jun 2016 //
PR NEWSWIRE
Alexza Pharmaceuticals to be Acquired by Ferrer
10 May 2016 //
PR NEWSWIRE
Alexza Pharmaceuticals Confirms Grupo Ferrer Non-binding Letter of Intent
26 Feb 2016 //
PR NEWSWIRE
